Vanguard Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,468,802
| Closed | -$2.2M | – | 4602 |
|
|
2023
Q1 | $2.2M | Buy |
1,468,802
+37,456
| +3% | +$56.2K | ﹤0.01% | 3634 |
|
|
2022
Q4 | $1.43M | Sell |
1,431,346
-2,079
| -0.1% | -$2.08K | ﹤0.01% | 3789 |
|
|
2022
Q3 | $2.58M | Buy |
1,433,425
+99,066
| +7% | +$178K | ﹤0.01% | 3640 |
|
|
2022
Q2 | $3.87M | Buy |
1,334,359
+303,462
| +29% | +$880K | ﹤0.01% | 3513 |
|
|
2022
Q1 | $2.85M | Sell |
1,030,897
-319,880
| -24% | -$883K | ﹤0.01% | 3801 |
|
|
2021
Q4 | $6.3M | Sell |
1,350,777
-103,295
| -7% | -$481K | ﹤0.01% | 3486 |
|
|
2021
Q3 | $12.4M | Buy |
1,454,072
+64,712
| +5% | +$551K | ﹤0.01% | 3124 |
|
|
2021
Q2 | $22.8M | Buy |
1,389,360
+17,857
| +1% | +$293K | ﹤0.01% | 2770 |
|
|
2021
Q1 | $30.3M | Buy |
1,371,503
+235,181
| +21% | +$5.19M | ﹤0.01% | 2589 |
|
|
2020
Q4 | $35.1M | Buy |
1,136,322
+47,231
| +4% | +$1.46M | ﹤0.01% | 2375 |
|
|
2020
Q3 | $22.1M | Buy |
1,089,091
+576,621
| +113% | +$11.7M | ﹤0.01% | 2405 |
|
|
2020
Q2 | $7.87M | Buy |
512,470
+25,467
| +5% | +$391K | ﹤0.01% | 2877 |
|
|
2020
Q1 | $3.77M | Buy |
487,003
+8,748
| +2% | +$67.7K | ﹤0.01% | 3092 |
|
|
2019
Q4 | $6.83M | Buy |
478,255
+12,886
| +3% | +$184K | ﹤0.01% | 3049 |
|
|
2019
Q3 | $6.99M | Buy |
465,369
+390,590
| +522% | +$5.87M | ﹤0.01% | 3008 |
|
|
2019
Q2 | $1.07M | Buy |
+74,779
| New | +$1.07M | ﹤0.01% | 3656 |
|